Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Novartis' pelacarsen failed to meet its primary endpoint in a late-stage study, impacting the cardiovascular drug market. Analysts expected peak sales of $4B-$5B. Eli Lilly's (LLY) stock declined only 3%, as its lepodisiran drug uses a different approach and Lilly has strong diabetes/obesity markets. Novartis (NVS) and Amgen (AMGN) are also developing Lp(a)-lowering drugs.
How this was made
The 30-second read
Why it matters
The failure of pelacarsen reshapes expectations for cardiovascular outcomes, potentially shifting investor focus to alternative mechanisms like lepodisiran and gene‑editing approaches.
Market read
First‑hand trial data creates immediate trading opportunities in major biotech stocks, with divergent impacts across peers.
What to watch
Lilly's strong diabetes/obesity franchise may cushion any downstream fallout from Lp(a) setbacks.
Background
The article discusses recent clinical trial outcomes in the Lp(a) lowering space, highlighting the competitive landscape among Novartis, Eli Lilly, Amgen, and Ionis.
Ticker impact
Novartis reported its late‑stage pelacarsen trial failed to meet the primary endpoint on Sept. 4, 2026.
downward pressure on NVS
First disclosure of a pivotal trial failure for a late‑stage asset.
Eli Lilly's stock fell only modestly after Novartis' pelacarsen failure, as Lilly pursues lepodisiran and other Lp(a) programs.
minor short‑term dip, long‑term outlook unchanged
Lilly's own Lp(a) program differs; market already priced limited reaction.
Amgen's shares sank 10% after the same pelacarsen failure news.
downward pressure on AMGN
Direct price reaction linked to the trial news.
Ionis Pharmaceuticals originally discovered pelacarsen, now licensed to Novartis.
potential modest decline
Only mentioned as originator; no direct financial exposure disclosed.
Market effects
Cardiovascular drug race faces heightened uncertainty; investors may re‑evaluate Lp(a) programs across peers.
US biotech sector sees mixed reactions; Novartis and Amgen pressured, Lilly relatively stable.
Large‑cap pharma news influences global healthcare indices.
Counterpoint
Novartis may benefit from focusing on other pipeline assets; the failure could free resources for higher‑potential programs.
Key entities
- companyNovartis
Swiss pharma giant reporting trial failure.
- companyEli Lilly
US pharma with lepodisiran program.
- companyAmgen
US biotech with its own Lp(a) candidate.
- companyIonis Pharmaceuticals
Developer of pelacarsen.
